31
Wed, Aug
13 New Articles

Arizona Instrument LLC is proud to announce the release of the Computrac® Vapor Pro® XL – the latest in a long line of accurate, reliable and easy to use moisture analyzers.

About the Vapor Pro® XL
The Vapor Pro® XL is a chemical free, moisture specific alternative to Karl Fischer titration. It features an upgraded heater, which increases the upper limit for testing temperatures to 300°C and allows for improved control over testing temperatures. The VPXL is also compatible with multiple sizes of sample vials and is equipped with stepped temperature testing capabilities for enhanced method development. The brand new touch screen and intuitive user interface make the Vapor Pro XL the most user friendly Computrac yet.

The Vapor Pro XL is ideal for nearly any application in which Karl Fischer is used. From plastics to petroleum products, pharmaceuticals to chemicals, the VPXL is the perfect fit for a wide variety of applications. Contact us today to learn more about the newest member of the Computrac family.

ASTM Methods

The Vapor Pro XL is can be used in accordance with:

  • ASTM D7191-10: Standard Test Method for Determination of Moisture in Plastics by Relative Humidity Sensor
  • ASTM D7546-15: Standard Test Method for Determination of Moisture in New and In-Service Lubricating Oils and Additives by Relative Humidity Sensor.

It also correlates well with popular methods, including: ASTM D6304-16, D6869-03, D1364-02, D4017-02,  D4928-12, E1064-16, D5530-15 and D4672-12.

About Arizona Instrument LLC

Arizona Instrument LLC introduced its first moisture analyzer in 1978 and quickly became an accepted leader in moisture analysis. The company is dedicated to providing precision moisture analysis instruments that are accurate, reliable and easy to use. Its Computrac® line of moisture analyzers includes both loss-on-drying instruments as well as chemical-free alternatives to Karl Fischer titration.

The Computrac® MAX® line of moisture, solids and ash analyzers was first introduced in 1982 and relies on the loss-on- drying and loss-on-ignition principles of operation. The MAX 4000XL is a rugged and reliable LOD instrument that works with a wide range of materials while the MAX 5000XL has the higher temperature capabilities of a muffle furnace, allowing for easy and repeatable moisture, solids and ash testing from a single sample.

The first Computrac® Vapor Pro® was introduced in 1996 as a chemical free alternative to Karl Fischer. The Vapor Pro XL builds upon the proven success of its predecessors while incorporating new features to improve repeatability, precision and flexibility. Arizona Instrument LLC also manufactures Jerome Hydrogen Sulfide and Mercury Vapor Analyzers.

Vapor-Pro-XL

Contact

analyzers or Jerome toxic gas analyzers,
please contact us online,
email us at This email address is being protected from spambots. You need JavaScript enabled to view it. or

give us a call at (800) 528-7411.
By Arizona Instrument LLC

Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Troxyca ER has properties that are expected to reduce abuse when crushed and administered by the oral and intranasal routes. However, abuse of Troxyca ER by these routes is still possible. It is the only oxycodone with oral abuse-deterrent features described in the labeling.

“Public health authorities and regulators have encouraged the development of treatments that are more difficult to abuse, yet offer pain relief to appropriate patients when used as indicated,” said Rory O’Connor, MD, Chief Medical Officer, Internal Medicine, Pfizer Inc. “The development of this medication with abuse-deterrent properties is another example of our ongoing commitment to advancing science and the treatment of patients with pain conditions.”

Troxyca ER extended-release capsules contain pellets that consist of oxycodone hydrochloride, an opioid agonist, which surround sequestered naltrexone hydrochloride, an opioid antagonist. When taken as directed, the naltrexone is intended to remain sequestered and patients receive oxycodone in an extended-release manner. Studies demonstrated that when the pellets are crushed the sequestered naltrexone is released and is available to counteract the effects of oxycodone.

The abuse-deterrent features of Troxyca ER were demonstrated in a battery of in vitro laboratory studies and three clinical abuse-potential studies utilizing crushed Troxyca ER by oral and intranasal routes of administration and the IV route (with simulated Troxyca ER).

Indication
Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release capsules, for oral use, CII is a combination opioid agonist/opioid antagonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Troxyca ER is contraindicated in patients with:

Significant respiratory depression
Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
Known or suspected gastrointestinal obstruction, including paralytic ileus
Hypersensitivity (e.g., anaphylaxis) to oxycodone or naltrexone or any other components of the Troxyca ER formulation

About Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com.

Biogen announced that Bioverativ will be the name of the standalone, publicly-traded global biotechnology company that it expects to launch in early 2017. Bioverativ will be focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. Following completion of the spin-off, Bioverativ plans to trade under the symbol BIVV on the NASDAQ Stock Market.

 

“As an independent and focused company, we believe that Bioverativ will be uniquely positioned to drive progress and advance the standard of care for people living with hemophilia,” said John G. Cox, Chief Executive Officer of Bioverativ, and Biogen’s former Executive Vice President, Pharmaceutical Operations & Technology. “Working closely with the hemophilia community, we hope to transform lives by accelerating innovation for people and caregivers living with hemophilia.”

 

“The new company’s name creates a clear connection to our Biogen heritage and biotech focus. It also conveys our commitment to actively working with patients, caregivers, health care professionals and advocacy leaders to create progress where patients need it most,” Mr. Cox continued.

 

Bioverativ will continue commercialization of ELOCTATE® and ALPROLIX®, indicated for the treatment of hemophilia A and B, respectively, under Biogen's existing collaboration agreement with Swedish Orphan Biovitrum AB (publ)(Sobi). After the spin-off, Bioverativ expects to continue development of ELOCTATE and ALPROLIX, including conducting studies to explore the potential benefits of Fc fusion technology on long-term joint health, immunogenicity and immune tolerance induction in hemophilia patients who develop inhibitors.

 

Bioverativ will also focus on advancing pipeline programs that address areas of unmet need in hemophilia and other blood disorders, including programs studying longer-acting factor therapies that utilize XTEN technology, a non-factor bi-specific antibody program to treat patients with hemophilia A and patients with inhibitors, and gene therapy programs for hemophilia A and B, as well as ongoing research relating to sickle cell disease.

 

Biogen announced its intent to spin-off its hemophilia business in May 2016. The spin-off is planned to be completed in early 2017, subject to the satisfaction of certain conditions, including, among others, final approval of Biogen’s board of directors, receipt of a favorable opinion with respect to the tax-free nature of the transaction, and the effectiveness of a Form 10 registration statement that is filed with the U.S. Securities and Exchange Commission (SEC). The initial Form 10 registration for Bioverativ is expected to be filed with the SEC later this week. The Bioverativ logo and visual identity will be unveiled at a later date.

 

About Biogen 

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com.

 

Contact:

Biogen 

MEDIA CONTACT:

Jason Glashow, +1 781-464-3260

This email address is being protected from spambots. You need JavaScript enabled to view it.

or

INVESTOR CONTACT:

Matt Calistri, +1 781-464-2442

This email address is being protected from spambots. You need JavaScript enabled to view it.

Teva Pharmaceutical Industries Ltd announced the launch of the generic equivalent to Gleevec®1(imatinib mesylate) tablets,100 mg and 400 mg, in the United States for multiple indications approved by the FDA.

 

Teva remains committed to strengthening its generics business with continued investment in new and diverse, high quality products. With nearly 375 generic medicines available, Teva has one of the largest portfolios of FDA-approved generic products on the market. The addition of this product to Teva’s oncology portfolio allows Teva to continue to grow in this therapeutic area.

Imatinib mesylate tablets had annual sales of approximately $2.42 billion in the United States, according to IMS data as of May 2016.

 

About Imatinib Mesylate Tablets

Imatinib mesylate tablets are indicated for: newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; patients with Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy; adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia; adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements; adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown; adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown; adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans; and adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive gastrointestinal stromal tumors (GIST) .

 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.

 

1 GLEEVEC® is a registered trademark of Novartis Oncology.

 

Teva Pharmaceutical Industries Ltd.

IR:

United States

Kevin C. Mannix, 215-591-8912

or

Ran Meir, 215-591-3033

or

Israel

Tomer Amitai, 972 (3) 926-7656

or

PR:

Israel

Iris Beck Codner, 972 (3) 926-7687

or

United States

Denise Bradley, 215-591-8974

or

Nancy Leone, 215-284-0213

 

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced Takeda Canada has received approval from Health Canada for NINLARO™ (ixazomib) capsules in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.In Canada, it is estimated that approximately 7,500 people live with multiple myeloma. The approval was primarily based on the results of the final analysis of the pivotal Phase 3 trial, TOURMALINE-MM1, which demonstrated that NINLARO in combination with lenalidomide and dexamethasone significantly extended progression-free survival, with a manageable safety profile in patients with relapsed/refractory multiple myeloma. Due to the high unmet need in multiple myeloma, the New Drug Submission for NINLARO was granted a Priority Review by Health Canada.

 

“Health Canada’s approval of NINLARO represents an important step in Takeda’s unwavering commitment to combat cancer by delivering novel therapies to patients as quickly, effectively and safely as possible,” says Chatrick Paul, General Manager at Takeda Canada. “We are one of the first countries in the world to gain marketing approval to deliver NINLARO as a critical treatment option for multiple myeloma patients. We are pleased that NINLARO – our first oncology prescription medicine in Canada – has a product label that is broad and robust, meaning Canadians living with relapsed/refractory multiple myeloma will now have a new effective treatment option available to them in the comfort of their home.” 

 

“Multiple myeloma, a devastating diagnosis for patients and their families, is a complicated disease that requires effective treatment options,” said Dr. Donna Reece, Professor and Director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Haematology at Princess Margaret Hospital/University of Toronto. “The approval of NINLARO offers a much-needed new option for Canadian patients with multiple myeloma who have received at least one prior therapy. Its oral delivery may help multiple myeloma patients overcome some of the logistical burdens they may face with current therapies, which are typically administered in-clinic or in-hospital requiring significant travel and time constraints.”

 

Marketing applications for NINLARO are currently under review by several regulatory authorities around the world.

 

About Takeda Pharmaceutical Company

 

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

 

Contacts

 

Canadian Media

Natacha Raphael

This email address is being protected from spambots. You need JavaScript enabled to view it.

+1 905-465-4149

 

European Media          

Kate Burd

This email address is being protected from spambots. You need JavaScript enabled to view it.

+44 7974 151510

 

Japan Media

Tsuyoshi Tada

This email address is being protected from spambots. You need JavaScript enabled to view it.

+81 (0) 3-3278-2417

 

Media outside Japan/EU/Canada

Sara Noonan

This email address is being protected from spambots. You need JavaScript enabled to view it.

+1-617-551-3683

 

Momenta Pharmaceuticals, Inc , a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Company has discontinued further accrual in its Phase 2 trial evaluating necuparanib in combination with Abraxane® and gemcitabine in patients with advanced metastatic pancreatic cancer.

 

The decision to discontinue enrollment into the study was based on the recommendation from the independent Data Safety Monitoring Board (DSMB) following a planned interim futility analysis conducted once 57 deaths (50% of the target number of 114 events required for trial completion) had occurred. Data were assessed from 120 randomized patients as of July 20, 2016. While no new safety signals were observed and the toxicity profile was considered manageable, the DSMB determined that necuparanib in combination with Abraxane and gemcitabine did not show a sufficient level of efficacy to warrant continued enrollment. Additionally, no new toxicities were observed that necessitate immediate discontinuation of study drug in patients currently active on protocol. The DSMB also recommended that the company consider unblinding the data to provide more information to determine how best to address ongoing patients.

 

"We are extremely disappointed with the outcome of the futility analysis - in particular, for those patients with pancreatic cancer where there is still so much unmet need for safe and effective therapy," said Jim Roach, M.D., Senior Vice President of Development and Chief Medical Officer of Momenta Pharmaceuticals. "We agree with the DSMB recommendations and plan to confirm the futility analysis and determine next steps for the necuparanib program."

 

"We are saddened that necuparanib did not produce the outcome we had hoped for in this patient population," said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. "We would like to thank the investigators and their brave patients for participating in this trial as well as our staff and external advisors for their support throughout this program."

 

The Phase 1/2 necuparanib trial is a two-part study in patients with advanced metastatic pancreatic cancer. Part A was a Phase 1, open-label, multiple ascending dose study of necuparanib given first as a single dose and then daily in combination with Abraxane and gemcitabine; final data from Part A was reported at the 2016 ASCO Annual Meeting. Part B is a Phase 2, randomized, placebo-controlled, double-blind study investigating the antitumor activity of necuparanib combined with Abraxane and gemcitabine compared with placebo combined with Abraxane and gemcitabine.

 

About Necuparanib

Necuparanib (M402) is a novel oncology drug candidate engineered to have a broad range of effects on tumor cells. The use of heparins to treat venous thrombosis in cancer patients has generated numerous reports of antitumor activity; however, the dose of these products has been limited by their anticoagulant activity. Leveraging its experience in deciphering the structure-function relationships of complex therapeutics, Momenta engineered necuparanib from unfractionated heparin to have significantly reduced anticoagulant activity while preserving relevant antitumor properties associated with heparins.

 

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

 

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release. The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

 

Investor Relations:

Sarah Carmody

Momenta Pharmaceuticals

1-617-395-5189

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Media Relations:

Karen Sharma

MacDougall Biomedical Communications

1-781-235-3060

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Amgen and Advaxis, Inc announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor. This collaboration brings together Amgen's development expertise in immuno-oncology with Advaxis' MINE™ (My Immunotherapy Neo-Epitopes) program, which is uniquely positioned to develop a customized approach to cancer treatment.

 

Under the terms of the agreement, Amgen receives exclusive worldwide rights to develop and commercialize ADXS-NEO. Amgen will make an upfront payment to Advaxis of $40 million and purchase $25 million of Advaxis common stock. Amgen will be fully responsible for funding clinical and commercial activities. Advaxis will lead the clinical development of ADXS-NEO through proof-of-concept, retain manufacturing responsibilities, and receive development, regulatory and sales milestone payments of up to $475 million and potential high single digit to mid-double digit royalty payments based on worldwide sales.

 

"Amgen's collaboration with Advaxis leverages and enhances our development and commercialization expertise in novel immuno-oncology treatments," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We look forward to partnering with Advaxis to advance this highly targeted and patient-specific treatment option for patients."

 

"Amgen is a pioneer in the science of using living cells to develop biologic medicines, making them an incredibly strong partner to develop and commercialize Advaxis' MINE," said Daniel J. O'Connor, president and chief executive officer at Advaxis. "With Amgen's resources, worldwide reach and a culture that embraces science and innovation, we are positioned to accelerate the clinical development program for ADXS-NEO to improve the lives of those who suffer from cancer."

 

The Advaxis Lm Technology™ utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to produce and deliver tumor antigen/adjuvant fusion proteins within antigen presenting cells with the goal of generating strong, T-cell-mediated immunity. For ADXS-NEO, DNA from each patient's primary tumor and/or metastases as well as normal cells, is sequenced and compared to identify mutations in genes coding for potential neo-antigens in the cancer. Advaxis then engineers and manufactures patient-specific Lm-LLO (listeriolysin O) vectors capable of immunizing them against neoepitopes exclusive to their cancer. After the ADXS-NEO infusion, neoepitope peptides corresponding to each patient's cancer-associated mutations are delivered directly into their antigen presenting cells by Lm-LLO, where they can stimulate cellular immune responses against multiple neoepitopes simultaneously. Clinical trials for ADXS-NEO are expected to begin in 2017.

 

About MINE™ (My Immunotherapy Neo-Epitopes) / ADXS-NEO

MINE™ (My Immunotherapy Neo-Epitopes) and ADXS-NEO are designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in each individual patient's tumor. This strategy, using massive parallel sequencing, eliminates the need for predictive algorithms and enables the development of truly personalized immunotherapies that can be manufactured in a manner that is cost-effective and timely for patients.

 

MINE™ will evaluate the immunologic and anti-tumor activity of this patient tumor-specific, neoepitope-based immunotherapy. Advaxis and Amgen will use learnings from MINE to identify and target neoepitopes using Lm Technology™ and later develop patient specific immunotherapy constructs that incorporate the neoepitope sequences identified in the patient's tumor cells. Clinical studies using ADXS-NEO are in development.

 

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

 

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

 

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology™, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer-fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology™ immunotherapy, axalimogene filolisbac (AXAL), targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted AXAL orphan drug designation for each of these three clinical settings, as well as a Special Protocol Assessment for the Phase 3 AIM2CERV trial in patients with high risk, locally advanced cervical cancer. AXAL has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the European Medicines Agency's Committee for Advanced Therapies. Advaxis has two additional immunotherapy products in human clinical development: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2-expressing solid tumors. Advaxis has received Fast Track Designation for ADXS-HER2 for the treatment of patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma and for AXAL for the treatment of high-risk locally advanced cervical cancer.

 

CONTACTS:

Amgen, Thousand Oaks

Kristen Neese, 805-313-8267 (media)

Trish Hawkins, 805-447-5631 (media)

Arvind Sood, 805-447-1060 (investors)

 

Advaxis, Inc.

Greg Mayes, Executive Vice President and COO

This email address is being protected from spambots. You need JavaScript enabled to view it.

609-250-7515

 

JPA Health Communications (media)

David Connolly

This email address is being protected from spambots. You need JavaScript enabled to view it. 

617-543-3915

 

More Articles ...

Market Movers

Rogers Corporation Common Stock

NYQ : ROG - 31 Aug, 4:02pm
55.91
-0.51 (-0.90%) After Hours:
Open 56.22 Mktcap 1.01B
High 56.35 52wk Hight 69.26
Low 55.64 52wk Low 41.92
Vol 110342 Avg Vol 137240
Eps 2.95 P/e 25.97
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 31 Aug, 4:02pm
4.48
+0.11 (+2.52%) After Hours:
Open 4.47 Mktcap 71.57B
High 4.51 52wk Hight 6.06
Low 4.45 52wk Low 3.60
Vol 7.28M Avg Vol 8.09M
Eps 0.37 P/e 13.49
Currency: USD

Merck & Company, Inc. Common St

NYQ : MRK - 31 Aug, 4:00pm
62.79
+0.08 (+0.13%) After Hours:
Open 63.08 Mktcap 173.63B
High 63.12 52wk Hight 64.00
Low 62.42 52wk Low 47.97
Vol 8.86M Avg Vol 9.83M
Eps 3.75 P/e 34.44
Currency: USD

Johnson & Johnson Common Stock

NYQ : JNJ - 31 Aug, 4:00pm
119.34
-0.13 (-0.11%) After Hours:
Open 119.54 Mktcap 326.50B
High 119.62 52wk Hight 126.07
Low 119.01 52wk Low 89.90
Vol 5.69M Avg Vol 6.81M
Eps 6.69 P/e 22.24
Currency: USD

: NOVN - 01 Jan,
() After Hours:
Open Mktcap
High 52wk Hight
Low 52wk Low
Vol Avg Vol
Eps 1.02 P/e
Currency:

Pfizer, Inc. Common Stock

NYQ : PFE - 31 Aug, 4:01pm
34.80
-0.08 (-0.23%) After Hours:
Open 34.86 Mktcap 211.08B
High 34.94 52wk Hight 37.39
Low 34.61 52wk Low 28.25
Vol 20.80M Avg Vol 21.81M
Eps 2.46 P/e 30.85
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 31 Aug, 4:00pm
13.20
+0.03 (+0.23%) After Hours:
Open 13.22 Mktcap
High 13.22 52wk Hight 17.52
Low 13.20 52wk Low 12.60
Vol 4687 Avg Vol 9078
Eps P/e
Currency: USD
Sign up via our free email subscription service to receive notifications when new information is available.